exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088295 RNA Name: hsa-miR-373-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53788748 End Site(bp): 53788770 External Links: hsa-miR-373-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand VLDLR chr9 2621787 2660056 + USP24 chr1 55066359 55215364 - CELF2 chr10 10798397 11336675 + APP chr21 25880550 26171128 - KLHL28 chr14 44924319 45042322 - RGMA chr15 93035273 93089204 - PFN2 chr3 149964904 150050788 - FAM177A1 chr14 35044907 35113130 + MBP chr18 76978827 77133683 - CUL1 chr7 148697914 148801110 + MSL1 chr17 40121971 40136917 + RIT1 chr1 155897808 155911404 - ATXN1 chr6 16299112 16761491 - ZFAND4 chr10 45615500 45672780 - SETD7 chr4 139495941 139606699 - BAZ1B chr7 73440406 73522293 - AMPD2 chr1 109616104 109632053 + SLC16A14 chr2 230034982 230068993 - PHC3 chr3 170086732 170181749 - FAM222B chr17 28755978 28855232 - PLEKHM1 chr17 45435900 45490749 - SYAP1 chrX 16719612 16765340 + ARL4A chr7 12686856 12690958 + RACGAP1 chr12 49976923 50033136 - LONP2 chr16 48244300 48363122 + CLIP4 chr2 29097705 29189643 + ADAR chr1 154582057 154628013 - MAGI3 chr1 113390515 113685923 + NAA16 chr13 41311267 41377030 + CLOCK chr4 55427903 55546909 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC125257.1 chr17 41848518 41851447 - AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.